This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Placebo Response in Generalized Anxiety: Its Effect on the Outcome of Clinical Trials

Edward Schweizer, M.D., and Karl Rickels, M.D.

Published: June 1, 1997

Article Abstract

The development of new treatments for generalized anxiety disorder increasingly has been sabotagedby a high placebo-response rate. As a consequence, and in contrast to the surge of approvals fornew antidepressants, only one new anxiolytic has been approved by the U.S. Food and Drug Administrationin the past 15 years. This article presents a brief review of factors that contribute to the placeboresponse in treatment studies of generalized anxiety. Since anxiety is a normal emotion that is sensitiveto a variety of life stresses, it is particularly difficult to achieve the primary goal of a clinical trial,which is to extract the "signal" of a drug effect from the "noise" of background fluctuations in symptoms.Data from the published literature and from the authors’ research unit concerning placeboresponsetrends are reviewed.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: Anxiety , Anxiolytics

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...